A Close Look at a Cancer Genome

DEREK LOWE | July 19, 2018

article image
Ever since gene sequencing became feasible (for several values of “feasible”!) it’s been of great interest to look at the genetic material of cancerous cells. It’s been clear from very early on that there are many changes, mutations, rearrangements, shifts, etc. in a cancer cell’s DNA, and it’s been equally clear that these do not tell a simple or clear-cut story. Genomic instability itself is a key feature of many tumor lines, and genomic instability comes in a lot of varieties.

Spotlight

Medichem, S.A.

Meet an independently-owned developer and manufacturer of Finished Dosage Forms (FDF) , Active Pharmaceutical Ingredients (API) and HPAPI. From its headquarters in Barcelona, Spain, Medichem has grown into one of the largest worldwide manufacturers of Generics and Chlorhexidine in the pharmaceutical industry. Made up of a workforce of 450 talented individuals located in Spain (HQ), the USA, Malta and China, Medichem serves 60 countries worldwide.

OTHER ARTICLES

Ruminating on Bioprocessing 4.0

Article | February 18, 2020

The Bioprocessing 4.0 concept seeks to apply automation and technology to the digital transformation of biologics manufacturing. As the paradigm moves forward, it faces barriers to its adoption, according to Eric Langer, president of BioPlan Associates. “Perhaps the greatest challenges involve unsecured links and adapting the applications to areas where automation is critically needed today,” says Langer. “Unresolved security issues could seriously affect a company’s data in a regulated environment, so they will need to have iron-clad anti-hacking protection in place. Unfortunately, cyber security is not yet a top focus for the industry.”

Read More

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | February 18, 2020

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More

Top 10 biotech IPOs in 2019

Article | February 18, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | February 18, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Spotlight

Medichem, S.A.

Meet an independently-owned developer and manufacturer of Finished Dosage Forms (FDF) , Active Pharmaceutical Ingredients (API) and HPAPI. From its headquarters in Barcelona, Spain, Medichem has grown into one of the largest worldwide manufacturers of Generics and Chlorhexidine in the pharmaceutical industry. Made up of a workforce of 450 talented individuals located in Spain (HQ), the USA, Malta and China, Medichem serves 60 countries worldwide.

Events